New Anti-Covid Drug That Reduces Dependence on Oxygen Will Be Out in a Month: DRDO Scientist


By: TNI Team
Updated: May 10, 2021 6:59

The new anti-Covid oral drug developed by the DRDO

will help hospitalized patients and reduce their supplemental

oxygen dependence. The drug 2-deoxy-D-glucose (2-DG) has

been developed by the Institute of Nuclear Medicine and

Allied Sciences (INMAS), a leading laboratory of Defence Research and

Development Organization (DRDO), in collaboration with Dr Reddy’s

Laboratories (DRL) in Hyderabad. The drug, which comes in powder

form in a sachet and is taken orally by dissolving it in water, was approved

by the Drugs Controller General of India (DCGI) for emergency use as

an adjunct therapy. News18, in an exclusive with the DRDO Project

Director and Scientist of 2-DG, Dr Sudhir Chandana, explains how

anti-Covid-19 therapeutic application of the drug will work on patients.

Also Read Story

Pollution Control: No PUC, No Fuel In Delhi From Oct 25

Speculations Rife About Appointment Of New CRPF DG

Kashmir: Journalist Offers Help To Student, Rapes Her Later

This New Cement Can Help India Meet CO2 Goals